Publication: Clinical Pharmacology & Therapeutics
Abstract
The IO Simulator™ is a Quantitative Systems Pharmacology platform implementing a mechanistic model of solid tumor–immune system interactions and the action of standard immuno-oncology drugs. Using a tarlatamab case study, the authors show how IO Simulator predicts combination therapy efficacy and cytokine biomarkers, which can be statistically related to the risk of cytokine release syndrome (CRS). This allows patient stratification and identification of doses that maximize efficacy without a substantial increase in cytokine release.
Authors: Daniela Santurio, Sirin Yonucu, Aiman Alam-Nazki, Birses Debir, Maciej Swat, Rachel H. Rose, Inmaculada C. Sorribes, Miao Zhao, Tomoko Freshwater, Piet H. van der Graaf, Andrzej M. Kierzek
Published: October 7, 2026
Oncology / Immuno-Oncology
Predict efficacy and safety before the next trial
See how a reusable QSP platform can support combination design in immuno-oncology. Explore Certara’s QSP capabilities and how the IO Simulator in Certara IQ(TM) can inform dose and combination decisions.
